Abstract 1127: Bcr-Abl inhibition in leukemia cells creates metabolic addictions

• Published in: Cancer research (Chicago, Ill.) Vol. 72; no. 8_Supplement; p. 1127
• Main Authors: Alvarez-Calderon, Francesca, Zaberezhnyy, Vadym, Gemta, Lelisa, Gregory, Mark A., DeGregori, James V.
• Format: Journal Article
• Language: English
• Published: 15.04.2012

Abstract Bcr-Abl kinase inhibitors are the standard therapy for chronic myelogenous leukemia (CML). While effective in controlling disease in chronic phase, these inhibitors often fail to completely eliminate Bcr-Abl+ CML cells and also fail to achieve durable remissions for advanced CML and Bcr-Abl...